Response to the COVID-19 vaccine variable in patients with multiple myeloma

HealthDay News – Multiple myeloma (MM) patients show a highly variable antibody response after receiving a two-dose mRNA Covid-19 vaccination schedule, according to a study published online in Cancer Cell on June 28.

Oliver Van Oekelen from the Icahn School of Medicine at Mount Sinai in New York City and colleagues analyzed the spike-binding immunoglobulin (Ig) G antibody levels of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 320 MM patients, the COVID-19 vaccinations (69.1 percent BNT162b2; 27.2 percent mRNA-1273; 3.8 percent unknown) in early 2021.

SARS-CoV-2 spike-binding IgG antibody levels were measured in 260 of the participants at least 10 days after receiving the second vaccine dose. The researchers found that 84.2 percent of the 260 participants had measurable SARS-CoV-2 spike-binding IgG antibody levels with significant fluctuations in the order of magnitude (median 149 AU / ml; range 5 to 7,882 AU / ml); 15.8 percent had values ​​below the detection limit. In a control group of 67 matching nurses, the antibody responses induced by the vaccine were more homogeneous (median 300 AU / ml; range 21 to 3,335 AU / ml); none had antibody levels below the detection limit. There were 10 cases of COVID-19 in MM patients after mRNA vaccination (seven after one dose; three after both doses). Six patients received outpatient treatment and four required subsequent hospitalization.

Continue reading

“Our results underscore the need for routine serological monitoring of MM patients after COVID-19 vaccination to enable personalized risk reduction measures related to mask relaxation and social distancing mandates for vaccinated individuals,” the authors write.

Several authors have disclosed financial ties to the biopharmaceutical industry; Mount Sinai’s Icahn School of Medicine has filed patent applications for SARS-CoV-2 serological tests and SARS-CoV-2 vaccines based on Newcastle disease virus, and has named a co-inventor.

Summary / full text (subscription or payment may be required)


COVID19 COVID19 Vaccine General Infectious Diseases General Medicine General Neurology

Related Articles